Megerlin F
Service de droit et d'économie de la santé, faculté des sciences pharmaceutiques et biologiques, université Paris Descartes, 4, avenue de l'Observatoire, 75006, Paris, France; Berkeley Center for Health Technology, University of California, Berkeley, États-Unis; GRADES, faculté de pharmacie, université Paris-Sud, 5, rue Jean-Baptiste Clément, 92296, Châtenay-Malabry cedex, France.
Ann Pharm Fr. 2013 Sep;71(5):291-301. doi: 10.1016/j.pharma.2013.08.004. Epub 2013 Sep 7.
Across global borders and throughout the various sectors of health care, the search for viable methods to pay for value has intensified. Driven by soaring costs and constrained budgets, public and private payers are seeking innovative ways to incentivize providers and product manufacturers to focus on effective outcomes for patients according to key performance indexes. Conditional pricing and performance-based payment for innovative medicines could facilitate access to quasi-monopsonic french market, in a context of financial crisis, loss of reciprocal confidence, and growing aversion for therapeutic and economical uncertainty. However, we consider these new methods of payment should not be termed "risk-sharing agreements", a misleading term despite its common use today. They also should not impact the national list prices of medicines, that is a decisive tool for stabilizing international trade.
